Crescita Therapeutics Inc. (CTX) Dips -1.72% on Mar 5

March 5, 2018 - By Winifred Garcia

Shares of Crescita Therapeutics Inc. (TSE:CTX) last traded at 0.57, representing a move of -1.72%, or -0.01 per share, on volume of 37,835 shares. After opening the trading day at 0.58, shares of Crescita Therapeutics Inc. traded in a close range. Crescita Therapeutics Inc. currently has a total float of 14.00M shares and on average sees 36,575 shares exchange hands each day. The stock now has a 52-week low of 0.48 and high of 1.2.

TSX: Leading Canada’s Growth

The equity market is a reliable indicator of any nation’s economic condition. Because of it, investors are able to determine the future of the economy and make investments based on logical numbers.

Canada has one of the world’s fastest growing economies’ thanks to its flourishing equity market that has withstood the toughest of times and still remains thriving until today.

The Canadian Equity Market

The Toronto Stock Exchange (TSX) is the main stock exchange in Canada. The benchmark index weighing its stocks is the S&P/TSX Composite Index, which makes up 70% of the total market capitalization of the TSX.

More than 1,500 companies are listed on the TSX as of October 2014. In May, the total market capitalization of the TSX was seen at nearly $3 trillion.
More than 200 companies are included in the S&P/TSX Composite Index, 36% of which belong to the Financials sector alone. The Energy sector is the second largest sector in the S&P/TSX Composite Index, making up 20% of it, followed by the Materials sector, Industrial sector, and Consumer Discretionary sector in the top five.

The S&P/TSX Composite Index has an all-time low of 217.50 and an all-time high of 15,657.63. Crescita Therapeutics Inc. trades on the exchange.

Trading on the TSX starts and ends at 9:30 a.m. and 4:00 p.m., respectively. Meanwhile, post-market trading starts and ends at 4:15 p.m. and 5:00 p.m., respectively.

How It Works

The S&P/TSX Composite Index measures stocks based on market capitalization with respect to share price. Such is the case to make sure that only the most actively traded stocks represent one of the world’s closely watched indices, providing accurate, real-time manifestations of the Canadian economy. This means that stocks held by the government, company insiders, and venture capitalists are not weighted on the S&P/TSX Composite Index.

For stocks to be included in the S&P/TSX Composite Index, they must first be listed on the TSX under the mandate of the Canadian government. They must make up at least 0.05% of the S&P/TSX Composite Index. This requirement guarantees a harmonious and perfectly balanced index. Crescita Therapeutics Inc. complies with the rules for listing.

Liquidity is also an important consideration in maintaining the S&P/TSX Composite Index. The trading volume of each stock must compose at least 0.025% of the total trading volume of all stocks eligible for inclusion. In terms of price, each stock must have a minimum average trading price of C$1 in the three months immediately preceding the review date. It must also have a minimum trading price of C$1 in the three trading days immediately preceding the rebalancing.

The Organization of the Petroleum Exporting Countries (OPEC) has finally decided to minimize oil production as an answer to the long-time problem of oversupply. This means that crude oil prices are set to bounce back from the turmoil, lifting the TSX further. Consequently, investing on TSX stocks is just reasonable for investors nowadays. Professional analysts might be interested how this will affect Crescita Therapeutics Inc..

More notable recent Crescita Therapeutics Inc. (TSE:CTX) news were published by: which released: “Crescita Therapeutics Inc.” on May 10, 2016, also with their article: “Crescita Therapeuticsâ„¢ Inc. Announces Acquisition of INTEGA Skin Sciences” published on September 01, 2016, published: “Crescita Therapeuticsâ„¢ Announces the Appointment of a New President” on April 12, 2017. More interesting news about Crescita Therapeutics Inc. (TSE:CTX) were released by: and their article: “Crescita Therapeuticsâ„¢ Inc. Provides Corporate Update” published on March 07, 2016 as well as‘s news article titled: “Crescita Therapeuticsâ„¢ Announces Acquisition of Alyria® Skincare Products” with publication date: August 08, 2017.

Crescita Therapeutics Inc., a dermatology company, provides over-the-counter and prescription products for the treatment and care of skin diseases and their symptoms. The company has market cap of $7.98 million. It owns various proprietary drug delivery platforms, including DuraPeel and MMPE that support the development of patented formulations, which facilitate the delivery of active drugs into or through the skin. It currently has negative earnings. The company's prescription products include Pliaglis, a topical local anaesthetic cream that provides dermal analgesia on intact skin prior to superficial dermatological procedures; Mical 1 that is in Phase II stage for the treatment of psoriasis; and Mical 2, which is in preclinical stage for the dermatological skin treatment.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: